☆ 4.6 Article

Tocilizumab in the treatment of COVID-19-a meta-analysis

QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2021)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Letter Virology

Elevated interleukin-6 is associated with severity of COVID-19: A meta-analysis

Jieyun Zhu et al.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹

Article Immunology

Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study

Michele Bartoletti et al.

Summary: The study showed a high incidence of CAPA among critically ill COVID-19 patients, and its occurrence seems to alter the natural course of the disease.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study

Javier Martinez-Sanz et al.

Summary: This study found that among hospitalized COVID-19 patients, receiving tocilizumab treatment significantly reduced the risk of death and intensive care unit admission or death in patients with high C-reactive protein levels.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

添加到收藏夹

Review Virology

Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis

Muhammad Aziz et al.

Summary: The efficacy of tocilizumab in severe COVID-19 patients appears to reduce mortality and the need for mechanical ventilation. Further randomized controlled trials are required to confirm these findings.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19

Shruti Gupta et al.

Summary: A multicenter cohort study found that early treatment with tocilizumab may reduce mortality among critically ill patients with COVID-19. Further research from randomized clinical trials is needed to confirm these findings.

JAMA INTERNAL MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial

Olivier Hermine et al.

Summary: In this clinical trial of COVID-19 patients with pneumonia requiring oxygen support but not in the ICU, tocilizumab did not reduce WHO-CPS scores below 5 by day 4 but may have reduced the risk of needing noninvasive ventilation, mechanical ventilation, or death by day 14. There was no difference in mortality by day 28. Further studies are needed to confirm these preliminary results.

JAMA INTERNAL MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia A Randomized Clinical Trial

Carlo Salvarani et al.

Summary: This study evaluated the use of tocilizumab in hospitalized COVID-19 pneumonia patients and found no significant benefit compared to standard care. Further randomized clinical trials with blinded, placebo-controlled methods are needed to confirm these results and explore potential applications of tocilizumab in different stages of the disease.

JAMA INTERNAL MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Carlos Salama et al.

Summary: Among hospitalized patients with Covid-19 pneumonia not on mechanical ventilation, tocilizumab reduced the risk of progression to mechanical ventilation or death, but did not improve overall survival. There were no new safety concerns identified.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

Viviane C. Veiga et al.

Summary: The study found that in patients with severe or critical COVID-19, tocilizumab in combination with standard care was not superior to standard care alone in improving clinical outcomes at 15 days, and it might increase mortality.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

I. O. Rosas et al.

Summary: In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Anthony C. Gordon et al.

Summary: Interleukin-6 receptor antagonists tocilizumab and sarilumab were found to improve outcomes, including survival, in critically ill patients with Covid-19 receiving organ support in ICUs according to an ongoing international trial. The efficacy of these treatments has been confirmed, with patients benefiting from the therapy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Zunyou Wu et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Medicine, General & Internal

Clinical Characteristics of Coronavirus Disease 2019 in China

W. Guan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Editorial Material Critical Care Medicine

Mechanical Ventilation in COVID-19: Interpreting the Current Epidemiology

Hannah Wunsch

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)

添加到收藏夹

Letter Medicine, General & Internal

COVID-19: consider cytokine storm syndromes and immunosuppression

Puja Mehta et al.

LANCET (2020)

添加到收藏夹

Article Critical Care Medicine

Core Outcomes Set for Trials in People With Coronavirus Disease 2019

Allison Tong et al.

CRITICAL CARE MEDICINE (2020)

添加到收藏夹

Letter Infectious Diseases

Interleukin-6 as prognosticator in patients with COVID-19

Elisa Grifoni et al.

JOURNAL OF INFECTION (2020)

添加到收藏夹

Article Medicine, General & Internal

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

John H. Stone et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Rheumatology

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Giovanni Guaraldi et al.

LANCET RHEUMATOLOGY (2020)

添加到收藏夹

Article Rheumatology

Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study

Noa Biran et al.

LANCET RHEUMATOLOGY (2020)

添加到收藏夹

Review Infectious Diseases

Reporting infections in clinical trials of patients with haematological malignancies

N. Tau et al.

CLINICAL MICROBIOLOGY AND INFECTION (2019)

添加到收藏夹

Review Rheumatology

A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases

Andrea Rubbert-Roth et al.

RHEUMATOLOGY AND THERAPY (2018)

添加到收藏夹

Review Critical Care Medicine

Clinical review: International comparisons in critical care - lessons learned

Srinivas Murthy et al.

CRITICAL CARE (2012)

添加到收藏夹

Article Rheumatology

Integrated safety in tocilizumab clinical trials

Michael H. Schiff et al.

ARTHRITIS RESEARCH & THERAPY (2011)

添加到收藏夹

Article Medicine, General & Internal

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Julian P. T. Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2011)

添加到收藏夹

Review Medicine, General & Internal

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

David Moher et al.

PLOS MEDICINE (2009)

添加到收藏夹

Article Medicine, General & Internal

Better reporting of harms in randomized trials: An extension of the CONSORT statement

JPA Ioannidis et al.

ANNALS OF INTERNAL MEDICINE (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.